Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Avere Therapeutics secures $500 million in a Private Placement to advance its oral IL-23 therapy AVR-001, supported by a notable investor syndicate.

RECENTLY ACQUIREDAug 10, 2026•about 4 hours ago

Amount Raised

$500 Million

Round Type

Post-IPO Equity

BiotechnologyHealth CareTherapeutics

Investors

Wedbush & Co., LlcUbs Investment BankEvercore IsiTd CowenJefferies

Description

Avere Therapeutics announced a $500 million private placement from leading healthcare investors to bolster its balance sheet and support the development of AVR-001. The funding is expected to fully finance Avere's operating plan into 2029. This follows a previously disclosed $320 million concurrent private investment. The combined proceeds will help advance Avere's lead program.

Company Information

Company

Avere Therapeutics

About

Avere Therapeutics, Inc. is a privately-held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases. They focus on developing differentiated treatment options to improve patient outcomes. The company's lead program, AVR-001, targets psoriasis and ulcerative colitis.

Related People

Suggested for you
2 contacts
Verified contactsJen, In a Creative Chapter hidden
Predictive Intelligence
Strategic

ML-powered predictions for Avere Therapeutics's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.